Patents by Inventor Volker Möhrle

Volker Möhrle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10696940
    Abstract: The invention provides a method for the continuous, microbe-reduced production and/or processing of a biopharmaceutical, biological macromolecular product from a heterogeneous cell culture-fluid mixture, comprising the steps of: (a) providing a particle-free fluid from a heterogeneous cell culture-fluid mixture containing the product, in the form of a product stream, (b) at least one filtration, providing a filtrate, (c) at least two chromatography steps for purifying the product, (d) at least one virus depletion, (e) at least one ultrafiltration and/or at least one diafiltration of the product stream of steps (b), (c) and/or (d), characterized in that the at least two chromatography steps from (c) comprise a purification via at least two chromatography columns and/or membrane adsorbers in each case and that the process is carried out in a closed and modular manner The invention further provides a corresponding modular system for carrying out said method.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 30, 2020
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Benjamin Maiser, Peter Schwan, Martin Lobedann, Volker Möhrle
  • Patent number: 10227559
    Abstract: The present invention provides a compounded cell culture medium powder formulation comprising: a basal medium powder and a cell culture media supplement, wherein the cell culture media supplement comprises and one or more salts; one or more growth factors; one or more inorganic ions; an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine; one or more buffers; and one or more anti-foaming agents. The invention further provides methods of making a compounded cell culture medium powder formulation methods of making a cell culture medium for growing mammalian cells and methods of producing a protein of interest by culturing cells in the cell culture medium and isolating the protein of interest.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: March 12, 2019
    Assignee: Bayer HealthCare LLC
    Inventors: Yuval Shimoni, Volker Möhrle
  • Publication number: 20180135006
    Abstract: The invention provides a method for the continuous, microbe-reduced production and/or processing of a biopharmaceutical, biological macromolecular product from a heterogeneous cell culture-fluid mixture, comprising the steps of: (a) providing a particle-free fluid from a heterogeneous cell culture-fluid mixture containing the product, in the form of a product stream, (b) at least one filtration, providing a filtrate, (c) at least two chromatography steps for purifying the product, (d) at least one virus depletion, (e) at least one ultrafiltration and/or at least one diafiltration of the product stream of steps (b), (c) and/or (d), characterized in that the at least two chromatography steps from (c) comprise a purification via at least two chromatography columns and/or membrane adsorbers in each case and that the process is carried out in a closed and modular manner The invention further provides a corresponding modular system for carrying out said method.
    Type: Application
    Filed: April 29, 2016
    Publication date: May 17, 2018
    Inventors: Benjamin MAISER, Peter SCHWAN, Martin LOBEDANN, Volker MÖHRLE
  • Publication number: 20180010090
    Abstract: Formulations and methods to increase the production of recombinant proteins, and other aspects, are disclosed. The formulations and methods relate to increasing mannose or calcium concentration, or both, in a cell culture medium formulation for culturing cells that express recombinant proteins. In some embodiments, a mammalian cell culture medium formulation is provided that has at least one of mannose at about 3.5 g/L or more and calcium in a range from about 1.5 mM to about 9.5 mM. Numerous other aspects and/or embodiments are provided.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 11, 2018
    Inventors: Yuval SHIMONI, Volker MÖHRLE, Venkatesh SRINIVASAN, Ricaredo MATANGUIHAN
  • Publication number: 20170191025
    Abstract: The present invention provides a compounded cell culture medium powder formulation comprising: a basal medium powder and a cell culture media supplement, wherein the cell culture media supplement comprises and one or more salts; one or more growth factors; one or more inorganic ions; an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine; one or more buffers; and one or more anti-foaming agents. The invention further provides methods of making a compounded cell culture medium powder formulation methods of making a cell culture medium for growing mammalian cells and methods of producing a protein of interest by culturing cells in the cell culture medium and isolating the protein of interest.
    Type: Application
    Filed: April 7, 2015
    Publication date: July 6, 2017
    Applicant: Bayer HealthCare LLC
    Inventors: Yuval SHIMONI, Volker MÖHRLE
  • Publication number: 20160002592
    Abstract: Formulations and methods to increase the production of recombinant proteins, and other aspects, are disclosed. The formulations and methods relate to increasing mannose or calcium concentration, or both, in a cell culture medium formulation for culturing cells that express recombinant proteins. In some embodiments, a mammalian cell culture medium formulation is provided that has at least one of mannose at about 3.5 g/L or more and calcium in a range from about 1.5 mM to about 9.5 mM. Numerous other aspects and/or embodiments are provided.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 7, 2016
    Inventors: Yuval Shimoni, Volker Moehrle, Venkatesh Srinivasan, Ricaredo Matanguihan
  • Publication number: 20150299638
    Abstract: Methods and perfusion culture systems are disclosed. The systems and methods relate to decreasing the starting perfusion rate, resulting in increased residence time of the cells in the bioreactor and the cell retention device, and/or concomitantly increasing the starting bioreactor volume or decreasing the starting cell retention device volume, or both. Other method embodiments include increasing the concentrations of individual components of the tissue culture fluid, and adding a stabilizer of the degradation of the recombinant protein.
    Type: Application
    Filed: October 9, 2013
    Publication date: October 22, 2015
    Applicant: Bayer HealthCare LLC
    Inventors: Yuval SHIMONI, Volker MOEHRLE, Venkatesh SRINIVASAN
  • Publication number: 20140099711
    Abstract: Methods and perfusion culture systems are disclosed. The systems and methods relate to decreasing the starting perfusion rate, resulting in increased residence time of the cells in the bioreactor and the cell retention device, and/or concomitantly increasing the starting bioreactor volume or decreasing the starting cell retention device volume, or both. Other method embodiments include increasing the concentrations of individual components of the tissue culture fluid, and adding a stabilizer of the degradation of the recombinant protein.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 10, 2014
    Inventors: Yuval Shimoni, Volker Moehrle, Venkatesh Srinivasan
  • Patent number: 8580547
    Abstract: The invention relates to novel PQQ-dependent soluble glucose dehydrogenases (sPQQGDH) which have an increased substrate specificity compared with the wild type, and also to methods for production and identification thereof.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: November 12, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Walter Weichel, Volker Möhrle, Markus Schindler, Rainhard Koch, Rolandas Meskys
  • Publication number: 20110236920
    Abstract: The invention relates to novel PQQ-dependent soluble glucose dehydrogenases (sPQQGDH) which have an increased substrate specificity compared with the wild type, and also to methods for production and identification thereof.
    Type: Application
    Filed: June 17, 2009
    Publication date: September 29, 2011
    Inventors: Walter Weichel, Volker Möhrle, Markus Schindler, Rainhard Koch, Rolandas Meskys
  • Patent number: 7312200
    Abstract: The present invention relates to derivatives of 9-keto spinosyns, which are substituted by a ?N—(O, NH or NRx)—Ry moiety in the C-9 position, to methods for their manufacture, and to their use for controlling animal pests.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: December 25, 2007
    Assignee: Bayer CropScience AG
    Inventors: Olga Malsam, Peter Lösel, Michael E. Beck, Ulrich Ebbinghaus-Kintscher, Robert Velten, Peter Jeschke, Volker Möhrle, Rita Fröde, Günther Eberz
  • Patent number: 7285653
    Abstract: The present invention relates to nucleic acid coding for enzyme activities of spinosyn biosynthesis and to the relevant enzymes per se. Furthermore, the invention relates to methods for preparing spinsoyn derivatives and spinosyn precursors.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: October 23, 2007
    Assignee: Bayer Aktiengesellschaft
    Inventors: Günther Eberz, Volker Möhrle, Rita Fröde, Robert Velten, José A. Salas
  • Patent number: 7034130
    Abstract: The present invention relates to methods for producing novel spinosyn derivatives which are substituted with a 1-hydroxy-ethyl radical in the C-21 position and to novel spinosyn derivatives of this type per se and to their use for producing novel spinosyns.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: April 25, 2006
    Assignee: Bayer Cropscience AG
    Inventors: Peter Jeschke, Günther Eberz, Rita Fröde, Volker Möhrle, Robert Velten